Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects with type 2 diabetes mellitus
On a stable regimen of metformin alone, metformin and a DPP4, metformin and a TZD, or metformin, a DPP4, and a TZD for a minimum of 3 months prior to randomization
Body mass indices \> 25 and \< 45 kg/m2
Hemoglobin A1c levels ≥ 7.0% and ≤ 11.0% at screening
Fasting C-peptide levels ≥ 0.2 nmol/L at screening
Subject with a history of hypertension must be on a stable antihypertensive treatment (s) (type of medication, dose, and regimen) for at least 6 weeks prior to the first dose of investigational product
Other criteria may apply
You may not be if
Subject has type 1 diabetes mellitus or history of type 1 diabetes mellitus
Subject has had 2 or more emergency room visits or hospitalizations due to poor glucose control in the 6 months prior to screening
Poorly controlled hypertension defined as diastolic pressure ≥ 95 mmHg or systolic ≥ 155 mmHg (confirmed by a repeat assessment) at screening
Triglycerides ≥ 400 mg/dL (4.52 mmol/L) at screening
Use of any known cytochrome P450 (CYP) inducers within 30 days or 5 half-lives (whichever is longer), prior to receiving the first dose of investigational product.
Use of any known inhibitors of CYP3A4/P-glycoprotein within the 14 days or 5 half lives (whichever is longer) prior to receiving the first dose of investigational product
Other criteria may apply
Clareo Health | Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects
